17 results
·
17ms
·
Sources: EU EUDAMED, US FDA
SCHOLTEN FRAME
FDA 510(k)
FDA Class 1
·General, Plastic Surgery
SW
FDA UDI
SW SAFETY SOLUTIONS INC.·00616489004059·PowerChem Neoprene Exam Gloves, Extra Large
Retention Cuff Inflator
FDA UDI
Bracco Diagnostics Inc.·10815112021228·One Shot Cuff Inflator
Retention Cuff Inflator
FDA UDI
Bracco Diagnostics Inc.·10815112020887·One Shot Cuff Inflator
Master Series
FDA UDI
AMERICAN ORTHODONTICS CORPORATION·00190746135545·DB BKT MASTER MAX RIGHT CUSPID 018 T-7 A+8 R=0
EDENTA
FDA UDI
EDENTA ETABLISSEMENT·E312K90044510001·Dowel Pin 15 mm
Mariner
FDA UDI
Seaspine Orthopedics Corporation·10889981129521·Screw Depth Adjuster, T30, Axial
Apex
FDA UDI
ORTHOXEL DESIGNATED ACTIVITY COMPANY·05391529584474·Apex Tibial Nail Ø 9.0 x 405mm
INTERCURE LTD. RESPI-LOW
FDA 510(k)
FDA Class 2
·Neurology
LIPIDPRO SYSTEM
FDA 510(k)
FDA Class 2
·Clinical Chemistry
ONETOUCHPING GLUCOSEMGMTSYSTEM
FDA Adverse Event
Malfunction
·ANIMAS CORPORATION·Product code LZG·June 27, 2014
UNKNOWN DEPUY PINNACLE METAL LINER
FDA Adverse Event
Injury
·DEPUY INTL., LTD.·Product code JDI·January 7, 2013
9800
FDA Adverse Event
Malfunction
·GE OEC MEDICAL SYSTEMS (SLC)·Product code JAA·October 26, 2010
SMR GLENOSPHERE Ø 40MM
FDA Adverse Event
Injury
·LIMACORPORATE S.P.A.·Product code KWS·December 15, 2021
SMR CTA HUMERAL HEAD Ø50 MM
FDA Adverse Event
Injury
·LIMACORPORATE S.P.A.·Product code HSD·August 29, 2022
OPTETRAK Comprehensive Knee System custom devices labeled as the following: a. CUSTOM OPTETRAK ANGLED PS INSERT (Product Line: 900-06-XX, 900-08-XX); b. CUSTOM OPTETRAK CC TIBIAL INSERT (Product Line: 900-23-XX, 900-30-XX); c. CUSTOM OPTETRAK CC INSERT (Product Line: 900-33-XX). NOTE: Information reflects Exactech recall expansion initiated on 02/07/2022.
FDA Enforcement
Class II
·Ongoing·Exactech, Inc.·October 13, 2021
VNS Therapy¿ AspireHC¿ Generator, VNS Therapy¿ AspireSR¿ Generator. Model No. 105. Product Usage: United States Indications for Use: Epilepsy (PMA 970003): The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. Depression (PMA 970003/S050): VNS Therapy is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. Indications outside the U.S.: Epilepsy (Non-US): The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizure (with or without secondary generalization) or generalized seizures that are refractory to antiepileptic medications. AspireSR (Seizure Response) features the Automatic Stimulation Mode which is intended for patients who experience seizures that are associated with cardiac rhythm increases known as ictal tachycardia. Depression (Non-US): The VNS Therapy System is indicated for the treatment of chronic or recurrent depression in patients who are experiencing a treatment-resistant or treatment-intolerant depressive episode.
FDA Enforcement
Class II
·Terminated·Cyberonics, Inc·August 23, 2017